Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

ELITE PHARMACEUTICALS INC /DE/

Form 3

November 06, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

TREPPEL JERRY

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

10/28/2008

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

ELITE PHARMACEUTICALS INC /DE/ [ELI]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O ELITE

PHARMACEUTICALS,

INC., Â 165 LUDLOW AVENUE

(Street)

(Check all applicable) 10% Owner _X_ Director

Officer Other (give title below) (specify below) 6. Individual or Joint/Group

Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

NORTHVALE. NJÂ 06830

(City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security

(Instr. 4)

Beneficially Owned

(Instr. 4)

3. Ownership 4. Nature of Indirect Beneficial Ownership

Form:

(Instr. 5) Direct (D) or Indirect

(I)

(Instr. 5)

2. Amount of Securities

By Wheaten HealthCare Partners,

Common Stock 180,000 Ι LP (1)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security 2. Date Exercisable and (Instr. 4)

Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security**

Conversion

Ownership

6. Nature of Indirect Beneficial Ownership

or Exercise Form of (Instr. 5)

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

			(Instr. 4)		Price of	Derivative	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Warrant (2)	09/15/2008	09/15/2013	Common Stock	30,488	\$ 0.25	I	By Wheaton HealthCare Partners, LP (1)
Warrant (3)	09/15/2008	09/15/2013	Common Stock	101,625	\$ 0.25	I	By Wheaton HealthCare Partners, LP (1)
Warrant (4)	09/15/2008	09/15/2013	Common Stock	750,000	\$ 0.25	I	By Wheaton HealthCare Partners, LP (1)
Series D 8% Convertible Preferred Stock (5)	09/15/2008	(6)	Common Stock	375,000	\$ 0.2	I	By Wheaton HealthCare Partners, LP (1)

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
DEDDEL JEDDY						

TREPPEL JERRY C/O ELITE PHARMACEUTICALS, INC. 165 LUDLOW AVENUE NORTHVALE, NJÂ 06830

 $\hat{A} X \qquad \hat{A} \qquad \hat{A} \qquad \hat{A}$

Signatures

/s/ Jerry Treppel 11/06/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) See Exhibit 99.1
- (2) See Exhibit 99.1
- (3) See Exhibit 99.1
- (4) See Exhibit 99.1
- (**5**) See Exhibit 99.1
- (6) See Exhibit 99.1

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2